Exelixis
EXEL
$21.06
Share price
-0.31%
Change (1 day)
7.97%
Change (1 year)
Categories
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.
Exelixis (EXEL) - Total debt
Total debt on the balance sheet as of March 2024 : $0.20 B
According to Exelixis's latest financial reports the company's total debt is $0.20 B. A company’s total debt is the sum of all current and non-current debts.
Exelixis - Total debt on balance sheet (from 2001 to 2024)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2023-12-31 | $0.18 B | -0.12% |
| 2022-12-31 | $0.19 B | 270.9% |
| 2021-12-31 | $51.27 M | 4.45% |
| 2020-12-31 | $49.08 M | 2.24% |
| 2019-12-31 | $48.01 M | 221.88% |
| 2018-12-31 | $14.91 M | -0.15% |
| 2017-12-31 | $14.93 M | -92.1% |
| 2016-12-31 | $0.18 B | -54.75% |
| 2015-12-31 | $0.41 B | 17.08% |
| 2014-12-31 | $0.35 B | 2.8% |
| 2013-12-31 | $0.34 B | 3.43% |
| 2012-12-31 | $0.33 B | 84.96% |
| 2011-12-31 | $0.18 B | -12.92% |
| 2010-12-31 | $0.20 B | 161.83% |
| 2009-12-31 | $79.61 M | -32.34% |
| 2008-12-31 | $0.11 B | -3.16% |
| 2007-12-31 | $0.12 B | -0.11% |
| 2006-12-31 | $0.12 B | -18.27% |
| 2005-12-31 | $0.14 B | 1.01% |
| 2004-12-31 | $0.14 B | 32.65% |
| 2003-12-31 | $0.11 B | 50.25% |
| 2002-12-31 | $73.93 M | 51.06% |
| 2001-12-31 | $48.94 M |
Total debt for similar companies or competitors
| Company | Total debt | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $33.63 B | 16,593.64% | 🇺🇸 USA |
 Pfizer PFE | $70.84 B | 35,064.74% | 🇺🇸 USA |
 Amgen AMGN | $64.61 B | 31,971.42% | 🇺🇸 USA |
 Sanofi SNY | $20.36 B | 10,009.45% | 🇫🇷 France |
 Merck MRK | $35.05 B | 17,299.96% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $57.40 B | 28,395.63% | 🇺🇸 USA |
 GlaxoSmithKline GSK | $22.45 B | 11,047.79% | 🇬🇧 UK |
 Curis CRIS | $2.79 M | -98.61% | 🇺🇸 USA |
 AVEO Oncology
AVEO | $38.68 M | -80.80% | 🇺🇸 USA |